You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / ABIM MOC / CE

Improving Outcomes in Patients With High-Risk HR-Positive/HER2-Negative Early Breast Cancer: Keeping the Patient Central

  • Authors: Joyce O'Shaughnessy, MD; Wolfgang Janni, MD, PhD; Sarah Donahue, MPH, NP, AOCNP; Miguel Martin, MD, PhD
  • CME / ABIM MOC / CE Released: 9/27/2022
  • Valid for credit through: 9/27/2023
Start Activity

  • Credits Available

    Physicians - maximum of 1.25 AMA PRA Category 1 Credit(s)™

    ABIM Diplomates - maximum of 1.25 ABIM MOC points

    Nurses - 1.25 ANCC Contact Hour(s) (1 contact hours are in the area of pharmacology)

    IPCE - 1.25 Interprofessional Continuing Education (IPCE) credit

    You Are Eligible For

    • Letter of Completion
    • ABIM MOC points

Target Audience and Goal Statement

This educational activity is intended for a global audience of hematology/oncology specialists, surgeons, pathologists, and nurses.

The goal of this activity is for learners to better understand the latest recommendations for risk assessment in hormone receptor (HR)+/human epidermal growth factor receptor 2 (HER2)- early breast cancer and management of patients with high risk; and, further, to improve skills for shared decision making and communication between the interprofessional team and the patient to improve adherence and persistence to oral anti-cancer therapies.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Latest clinical trial data investigating oral anti-cancer therapies for the treatment of patients with HR+/HER2- early breast cancer
  • Have greater competence related to
    • Assessing risk of recurrence in patients with HR+/HER2- early breast cancer
    • Optimizing management of patients with high-risk HR+/HER2- early breast cancer
  • Demonstrate greater confidence in their ability to
    • Apply best practices for shared decision making and communication between the interprofessional team and patient to improve adherence and persistence to oral anti-cancer therapies


Disclosures

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.


Faculty

  • Joyce O'Shaughnessy, MD

    Medical Oncology Specialist
    Celebrating Women Chair in Breast Cancer Research
    Baylor University Medical Center
    Director, Breast Cancer Research Program
    Texas Oncology and US Oncology
    ​Dallas, Texas, United States

    Disclosures

    Joyce O’Shaughnessy, MD, has the following relevant financial relationships:
    Consultant or advisor for: AbbVie, Inc.; Agendia; Amgen Biotechnology; Aptitude Health; AstraZeneca; Bayer; Bristol Myers Squibb; Celgene Corporation; Clovis Oncology; Daiichi Sankyo; Eisai; G1 Therapeutics; Genentech; Gilead Sciences; GRAIL; Halozyme Therapeutics; Heron Therapeutics; Immunomedics; Ipsen Biopharmaceuticals; Lilly; Merck; Myriad; Nektar Therapeutics; Novartis; Ontada; Pfizer; Pharmacyclics; Pierre Fabre Pharmaceuticals; Prime Oncology; Puma Biotechnology; Roche; Samsung Bioepis; Sanofi; Seagen Inc.; formerly Seattle Genetics; Inc.; Syndax Pharmaceuticals; Taiho Oncology; Takeda; Synthon

  • Wolfgang Janni, MD, PhD

    Medical Director
    Womens Clinic
    Director, Department of Obstetrics and Gynecology
    University Hospital Ulm
    Ulm, Germany

    Disclosures

    Wolfgang Janni, MD, PhD, has the following relevant financial relationships:
    Consultant or advisor for: AstraZeneca; Celgene; Chugai; Daiichi Sankyo; Eisai; Exact Science; GlaxoSmithKline; Janssen; Lilly; Menarini; Merck Sharp & Dohme, Corp.; Novarits; Pfizer; Roche; Sanofi-Aventis; Seagen Inc., formerly Seattle Genetics, Inc.
    Speaker or member of speakers bureau for: Speaker or member of speakers bureau for: AstraZeneca; Celgene; Chugai; Daiichi Sankyo; Eisai; Exact Science; GlaxoSmithKline; Janssen; Lilly; Menarini; Merck Sharp & Dohme, Corp.; Novartis; Pfizer; Sanofi-Aventis; Seagen, Inc., formerly Seattle Genetics, Inc.
    Research funding from: AstraZeneca; Celgene; Chugai; Daiichi Sankyo; Eisai; Exact Science; GlaxoSmithKline; Janssen; Lilly; Menarini; Merck Sharp & Dohme, Corp.; Novartis; Pfizer; Roche; Sanofi-Aventis; Seagen, Inc., formerly Seattle Genetics, Inc.

  • Sarah Donahue, MPH, NP, AOCNP

    Nurse Practitioner
    Carol Franc Buck Breast Cancer Center
    Helen Diller Family Comprehensive Cancer Center
    University of California, San Francisco
    San Francisco, California, United States

    Disclosures

    Sarah Donahue, MPH, NP, AOCNP, has the following relevant financial relationships:
    Consultant or advisor for: Sanofi Genzyme

  • Miguel Martin, MD, PhD

    Professor of Medicine
    Head, Medical Oncology Service
    Hospital General Universitario Gregorio Marañón
    Universidad Complutense
    ​Madrid, Spain

    Disclosures

    Miguel Martin, MD, PhD, has the following relevant financial relationships:
    Consultant or advisor for: AstraZeneca; Daiichi Sankyo; Lilly; Novartis; Pfizer; Pierre-Fabre; Roche/Genentech; Seagen Inc., formerly Seattle Genetics, Inc.; Taiho Pharmaceutical
    Speaker or member of speakers bureau for: Daiichi Sankyo; Lilly; Pfizer; Roche/Genentech; Seagen Inc., formerly Seattle Genetics, Inc.

Editor

  • Davecia Ragoonath-Cameron, MS

    Medical Education Director, Medscape, LLC

    Disclosures

    Davecia R. Cameron, MS, has no relevant financial relationships.

Compliance Reviewer/Nurse Planner

  • Leigh Schmidt, MSN, RN, CNE, CHCP

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Leigh Schmidt, MSN, RN, CNE, CHCP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.


Accreditation Statements



In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity was planned by and for the healthcare team, and learners will receive 1.25 Interprofessional Continuing Education (IPCE) credit for learning and change.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    Contact This Provider

    For Nurses

  • Awarded 1.25 contact hour(s) of nursing continuing professional development for RNs and APNs; 1.0 contact hours are in the area of pharmacology.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / ABIM MOC / CE

Improving Outcomes in Patients With High-Risk HR-Positive/HER2-Negative Early Breast Cancer: Keeping the Patient Central

Authors: Joyce O'Shaughnessy, MD; Wolfgang Janni, MD, PhD; Sarah Donahue, MPH, NP, AOCNP; Miguel Martin, MD, PhDFaculty and Disclosures

CME / ABIM MOC / CE Released: 9/27/2022

Valid for credit through: 9/27/2023

processing....

Educational Impact Challenge

The goal of this activity is for learners to better understand the latest recommendations for risk assessment in hormone receptor (HR)+/human epidermal growth factor receptor 2 (HER2)- early breast cancer and management of patients with high risk; and, further, to improve skills for shared decision making and communication between the interprofessional team and the patient to improve adherence and persistence to oral anti-cancer therapies.

Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.

  • Print